Cardiac Fibrosis and Remodeling
Research Guide

The healing myocardium sequentially mobilizes two monocyte subsets post-myocardial infarction: Ly-6C high monocytes clear debris and necrotic cardiomyocytes, while Ly-6C low monocytes promote repair and angiogenesis. These divergent functions orchestrate granulation tissue formation and scar maturation, as shown in 'The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions' (Nahrendorf et al., 2007). This balance prevents excessive fibrosis and supports functional recovery.

Endothelial cells undergo endothelial-to-mesenchymal transition, acquiring fibroblast-like features and producing extracellular matrix components that drive fibrosis. This process occurs in response to transforming growth factor-β signaling in injured hearts, exacerbating remodeling as detailed in 'Endothelial-to-mesenchymal transition contributes to cardiac fibrosis' (Zeisberg et al., 2007). Targeting this transition reduces fibrotic burden in experimental models.

Calcineurin activates a transcriptional pathway inducing hypertrophic gene expression in cardiomyocytes via nuclear factor of activated T-cells. This pathway drives pathological hypertrophy contributing to remodeling, as demonstrated in 'A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy' (Molkentin et al., 1998). Inhibition of calcineurin prevents hypertrophy in transgenic models.

Bone marrow cells, including hematopoietic stem cells, regenerate infarcted myocardium by differentiating into cardiomyocytes and vascular cells, improving function and survival. Studies like 'Bone marrow cells regenerate infarcted myocardium' (Orlic et al., 2001) and 'Mobilized bone marrow cells repair the infarcted heart, improving function and survival' (Orlic et al., 2001) show structural and functional integration with host tissue. Clinical translation appears in the BOOST trial ('Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial' (Wollert et al., 2004)).

Necrotic cardiomyocytes release danger signals post-infarction, activating innate immune pathways and triggering intense inflammation mediated by cytokines like tumor necrosis factor. This response clears debris but must resolve to avoid adverse remodeling, per 'The inflammatory response in myocardial infarction' (Frangogiannis, 2002) and 'The Biological Basis for Cardiac Repair After Myocardial Infarction' (Prabhu and Frangogiannis, 2016). Optimal timing of interventions depends on this inflammatory timeline.